Payment overview · 2025
General Payments
$1,079.42
28 reported records · 11 companies
Healthcare provider profile · identity verified
Joy Bell, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · AURORA, MO · NPI 1386112613
Verified facts
What the public records show
CMS Open Payments records show Joy Bell, NP received $1,079.42 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BYETTA as an associated drug or biological on 60 records involving 49 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Byetta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $406.02 | 37.6% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $155.37 | 14.4% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $122.17 | 11.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $121.70 | 11.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $104.57 | 9.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $54.05 | 5.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.87 | 4.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.75 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.13 | 1.8% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.37 | 1.4% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $14.42 | 1.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,079.42 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $225.43 | 9 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $136.37 | 3 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $122.17 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $121.70 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $104.57 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $104.57 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $77.29 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $62.47 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $54.05 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $45.87 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $14.42 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BYETTA open payments reported associated product |
CMS Open Payments — General Payments 60 supporting records · 49 recipient NPIs · example record 1206154618 |
Byetta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 73 |
| Gabapentin | Gabapentin | 228 | 50 |
| Lisinopril | Lisinopril | 180 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 53 |
| Liothyronine Sodium | Liothyronine Sodium | 160 | 36 |
| Omeprazole | Omeprazole | 143 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 141 | 31 |
| Progesterone | Progesterone, Micronized | 129 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 128 | 33 |
| Estradiol | Estradiol | 110 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 31 |
| Trazodone Hcl | Trazodone Hcl | 106 | 20 |
| Montelukast Sodium | Montelukast Sodium | 103 | 23 |
| Furosemide | Furosemide | 101 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 30 |
| Carvedilol | Carvedilol | 91 | 20 |
| Potassium Chloride | Potassium Chloride | 80 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 18 |
| Metformin Hcl Er | Metformin Hcl | 62 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 11 |
| Eliquis | Apixaban | 58 | 11 |
| Metformin Hcl | Metformin Hcl | 58 | 17 |
| Telmisartan | Telmisartan | 54 | suppressed |
| Nabumetone | Nabumetone | 51 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 15 |
| Prednisone | Prednisone | 45 | 30 |
| Meloxicam | Meloxicam | 43 | 13 |
| Bumetanide | Bumetanide | 41 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 35 |
| Colchicine | Colchicine | 36 | suppressed |
| Losartan Potassium | Losartan Potassium | 36 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Np Thyroid | Thyroid,pork | 28 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 11 |
| Lactulose | Lactulose | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Glipizide Er | Glipizide | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Byetta | Exenatide | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,079.42 · 28 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, FABRAZYME, FARXIGA, FREESTYLE LIBRE, NP Thyroid 60, NURTEC ODT, SMARTVEST, The Cologuard Plus Collection Kit, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error